Evidence map›Paper›PMID 36199692›Full record

ArticleFrontiers in pharmacology2022

A bibliometric research based on hotspots and frontier trends of denosumab.

Bolin Ren, Xiaolei Ren, Lu Wang, Chao Tu, Wenchao Zhang, Zhongyue Liu, Lin Qi, Lu Wan, Ke Pang, Cheng Tao and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Bolin RenDepartment of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, China.
Xiaolei RenDepartment of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, China.
Lu WangDepartment of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, China.
Chao TuDepartment of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, China.
Wenchao ZhangDepartment of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, China.
Zhongyue LiuDepartment of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, China.
Lin QiDepartment of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, China.
Lu WanDepartment of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, China.
Ke PangDepartment of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, China.
Cheng TaoDepartment of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, China.
Zhihong LiDepartment of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, China.
Second Xiangya Hospital of Central South University · CNCentral South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Denosumab is a monoclonal antibody that targets and inhibits the osteoclast activating factor receptor activator for nuclear factor-κB ligand (RANKL). It has been widely used in the treatment of osteoporosis, giant cell tumors of bone, and in the prevention of malignant skeletal-related events (SREs). We collected the research results and related MeSH terms of denosumab from 2011 to 2021 through the Web of Science and PubMed, respectively. The literature was visualized and analyzed by CiteSpace and bibliometric online analysis platforms. The MeSH terms were biclustered using the Bibliographic Co-Occurrence Analysis System (BICOMB) and graph clustering toolkit (gCLUTO). The results show that the number of denosumab-related annual publications had increased from 51 to 215, with the United States leading and Amgen Inc. being the most influential in the past 10 years. Articles published in the Journal of Bone and Mineral Research had the highest total citations. Three scholars from Shinshu University in Matsumoto, Yukio Nakamura, Takako Suzuki, and Hiroyuki Kato, joined the field relatively late but produced the most. The clinical comparison and combination of denosumab with other drugs in the treatment of osteoporosis was the most significant focus of research. Drug withdrawal rebound and management strategies have gained more attention and controversy recently. MeSH analysis revealed eight major categories of research hotspots. Among them, exploring the multiple roles of the RANK-RANKL-OPG system in tumor progression, metastasis, and other diseases is the potential direction of future mechanism research. It is a valuable surgical topic to optimize the perioperative drug administration strategy for internal spinal fixation and orthopedic prosthesis implantation. Taken together, the advantages of denosumab were broad and cost-effective. However, there were still problems such as osteonecrosis of the jaw, severe hypocalcemia, a high recurrence rate of giant cells in the treatment of bone and individual sarcoidosis, and atypical femoral fractures, which need to be adequately solved.

Indexed as

bibliometric and network analysisbiclustering analysisdenosumabosteoporosisRANKL

Identifiers

PMID36199692
PMCPMC9527327
OpenAlexW4296354244

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.